Vaccine Branch, Center for Cancer Research, National Cancer Institute, United States.
Vaccine Branch, Center for Cancer Research, National Cancer Institute, United States.
Curr Opin Immunol. 2018 Apr;51:111-122. doi: 10.1016/j.coi.2018.03.001. Epub 2018 Mar 16.
Therapeutic cancer vaccines have been a long-sought approach to harness the exquisite specificity of the immune system to treat cancer, but until recently have not had much success as single agents in clinical trials. However, new understanding of the immunoregulatory mechanisms exploited by cancers has allowed the development of approaches to potentiate the effect of vaccines by removing the brakes while the vaccines step on the accelerator. Thus, vaccines that had induced a strong T cell response but no clinical therapeutic effect may now reach their full potential. Here, we review a number of promising approaches to cancer vaccines developed initially in mouse models and their translation into clinical trials, along with combinations of vaccines with other therapies that might allow cancer vaccines to finally achieve clinical efficacy against many types of cancer.
治疗性癌症疫苗一直是一种备受期待的方法,旨在利用免疫系统的高度特异性来治疗癌症,但直到最近,作为单一药物在临床试验中并没有取得太大的成功。然而,人们对癌症利用的免疫调节机制有了新的认识,这使得人们能够开发出一些方法,通过在疫苗加速时去除刹车,来增强疫苗的效果。因此,以前那些能够诱导强烈 T 细胞反应但没有临床治疗效果的疫苗,现在可能会发挥出它们的全部潜力。在这里,我们回顾了一些在小鼠模型中最初开发的有前途的癌症疫苗方法,并将其转化为临床试验,以及与其他疗法联合使用的疫苗,这些方法可能使癌症疫苗最终对多种类型的癌症实现临床疗效。